Kraskowski O, Stratmann JA, Wiesweg M, Eberhardt W, et al. Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting. J Cancer Res Clin Oncol 2023 May 18. doi: 10.1007/s00432-023-04839.
PMID: 37198447